OMER heads into its June 18 earnings report with the lending pool completely dry and short sellers holding near a quarter of the float.
The borrow picture is the sharpest signal this week. Availability has collapsed to zero — every share available to lend is already lent out, the tightest reading of the past year. That's not a one-day anomaly; the data shows availability has been at or near zero for most of the past month, with only brief, shallow reprieves above 5%. Cost to borrow has moved in the same direction, more than tripling since early May to nearly 2.85% and spiking as high as 4.24% mid-week. For a name with 24% of free float already short, that combination leaves very little room for new short positions to be established cheaply. The ORTEX short score sits at 83, ranking in roughly the bottom 2% of the universe on both days-to-cover and borrow availability — a configuration that historically flags elevated short-squeeze sensitivity.
Short interest itself has edged higher over the past month, up roughly 4% in share terms to just under 17 million shares. The week-on-week move was a modest +1.7%, consistent with a position that is holding rather than building aggressively. Days to cover, per the FINRA settlement data, runs to nine days — meaning any meaningful covering event would take time to play out. Options positioning has drifted more cautious too: the put/call ratio is running above its recent average at 0.61, about 1.3 standard deviations above the 20-day mean of 0.46. That's elevated but not extreme — well below the 52-week high of 1.01. The shift in the PCR tracks almost exactly with the stock's 29% decline over the past month, down from above $14 to the current $9.97.
The Street's bullish thesis rests almost entirely on YARTEMLEA's commercial trajectory. HC Wainwright reiterated its Buy and $40 target as recently as today, while D. Boral Capital holds at Buy with a $36 target. Both firms point to YARTEMLEA's newly assigned J-code as a potential catalyst for reimbursement clarity and faster hospital adoption, with pipeline candidates OMS1029 and OMS527 adding optionality. The bear case is simpler: YARTEMLEA launched into a complex reimbursement environment, Omidria royalties generate limited cash flow, and the company remains deeply unprofitable. The $40 mean target against a $9.97 close implies substantial implied upside on paper, but the gap largely reflects the speculative nature of the coverage rather than near-term fundamental convergence. Valuation multiples are not meaningful for a company generating negative earnings and book value.
Institutional ownership offers a modest counterweight to the short positioning. BlackRock added roughly 247,000 shares through May, lifting its stake to 7.3% of shares outstanding. State Street added 346,000 shares in the same period. On the insider side, the most recent action — a $87,000 sale by the Lead Independent Director in late May — is too small to carry much signal. More notable is that founder and CEO Gregory Demopulos trimmed 357,000 shares in February at $11.93, a sale that preceded the stock's further 16% slide to current levels. The last purchase on record from a Demopulos family member was Peter Demopulos adding 600,000 shares, though that reporting date aligns with April's filing window.
Earnings history sharpens the stakes: the May 14 print sent the stock down 14.8% the next day and 16.8% over the following five sessions. The prior event delivered a similar 10% next-day loss. With availability exhausted, short interest anchored near 24% of float, and the next print just eight days away, the degree to which YARTEMLEA sales data and reimbursement progress either confirm or disappoint the bull narrative will be the central variable to watch.
See the live data behind this article on ORTEX.
Open OMER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
